Carol H. Pretswell

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

P. Kalra, D. McAuley, G. Glenn, 2021, The New England journal of medicine.

Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant

D. Moodley, S. Madhi, V. Shinde, 2021, The New England journal of medicine.

Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial

Adam C. Champion, Jane E. Ewing, M. Elnaggar, 2021, The Lancet Respiratory Medicine.

The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70

A. Schaefer, Shinn-Jang Hwang, G. Icardi, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination

Hyo Youl Kim, Kenjiro Nakamura, A. Schaefer, 2022, Open forum infectious diseases.

Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial

J. Bradley, P. Kalra, G. Glenn, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.1.7 Variant

P. Kalra, D. McAuley, G. Glenn, 2021, medRxiv.